NO994998L - Fusjonsproteiner - Google Patents

Fusjonsproteiner

Info

Publication number: NO994998L
Authority: NO; Norway
Prior art keywords: fusion proteins; tgf; treat; variety; methods
Prior art date: 1997-04-18

Application number

NO994998A

Other languages

English (en)

Norwegian (no)

Other versions

NO994998D0 (no

Inventor

Philip Gotwals

Victor Koteliansky

Richard Cate

Michelle Sanicola-Nadel

Original Assignee

Biogen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-18

Filing date

1999-10-14

Publication date

1999-12-20

1999-10-14 Application filed by Biogen Inc filed Critical Biogen Inc

1999-10-14 Publication of NO994998D0 publication Critical patent/NO994998D0/no

1999-12-20 Publication of NO994998L publication Critical patent/NO994998L/no

Links

102000037865 fusion proteins Human genes 0.000 title abstract 3
108020001507 fusion proteins Proteins 0.000 title abstract 3
108060003951 Immunoglobulin Proteins 0.000 abstract 1
102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 abstract 1
108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 abstract 1
230000000893 fibroproliferative effect Effects 0.000 abstract 1
102000018358 immunoglobulin Human genes 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Physics & Mathematics (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Rheumatology (AREA)
Neurology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Toxicology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)

NO994998A 1997-04-18 1999-10-14 Fusjonsproteiner NO994998L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US4464197P	1997-04-18	1997-04-18
PCT/US1998/007587 WO1998048024A1 (en)	1997-04-18	1998-04-16	Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins

Publications (2)

Publication Number	Publication Date
NO994998D0 NO994998D0 (no)	1999-10-14
NO994998L true NO994998L (no)	1999-12-20

Family

ID=21933495

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO994998A NO994998L (no)	1997-04-18	1999-10-14	Fusjonsproteiner

Country Status (22)

Country	Link
US (1)	US20050203022A1 (de)
EP (1)	EP0975771B1 (de)
JP (2)	JP2001515360A (de)
KR (1)	KR20010006534A (de)
CN (1)	CN1257545A (de)
AT (1)	ATE366816T1 (de)
AU (1)	AU737106B2 (de)
BR (1)	BR9808934A (de)
CA (1)	CA2286933A1 (de)
DE (1)	DE69838061T2 (de)
DK (1)	DK0975771T3 (de)
EA (1)	EA199900947A1 (de)
EE (1)	EE9900492A (de)
ES (1)	ES2289778T3 (de)
IL (1)	IL132249A0 (de)
IS (1)	IS5217A (de)
NO (1)	NO994998L (de)
NZ (1)	NZ500284A (de)
PL (1)	PL336306A1 (de)
PT (1)	PT975771E (de)
TR (1)	TR199902878T2 (de)
WO (1)	WO1998048024A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6171820B1 (en)	1995-12-07	2001-01-09	Diversa Corporation	Saturation mutagenesis in directed evolution
US5830696A (en)	1996-12-05	1998-11-03	Diversa Corporation	Directed evolution of thermophilic enzymes
US6562594B1 (en)	1999-09-29	2003-05-13	Diversa Corporation	Saturation mutagenesis in directed evolution
US6740506B2 (en)	1995-12-07	2004-05-25	Diversa Corporation	End selection in directed evolution
US6713279B1 (en)	1995-12-07	2004-03-30	Diversa Corporation	Non-stochastic generation of genetic vaccines and enzymes
US7018793B1 (en)	1995-12-07	2006-03-28	Diversa Corporation	Combinatorial screening of mixed populations of organisms
US6361974B1 (en)	1995-12-07	2002-03-26	Diversa Corporation	Exonuclease-mediated nucleic acid reassembly in directed evolution
US6352842B1 (en)	1995-12-07	2002-03-05	Diversa Corporation	Exonucease-mediated gene assembly in directed evolution
US6537776B1 (en)	1999-06-14	2003-03-25	Diversa Corporation	Synthetic ligation reassembly in directed evolution
US6358709B1 (en)	1995-12-07	2002-03-19	Diversa Corporation	End selection in directed evolution
US6939689B2 (en)	1995-12-07	2005-09-06	Diversa Corporation	Exonuclease-mediated nucleic acid reassembly in directed evolution
US6238884B1 (en)	1995-12-07	2001-05-29	Diversa Corporation	End selection in directed evolution
US6492325B1 (en)	1998-05-22	2002-12-10	Boys Town National Research Hospital	Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
AU4572899A (en) *	1998-06-16	2000-01-05	Biogen, Inc.	Variant type ii tgf-beta receptor fusion proteins and methods
DE1221490T1 (de)	1999-09-17	2003-05-28	Tgt Lab S A De C V	Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von unterschiedlichen typen der leber-, nieren- und lungenfibrose und hypertrophischen narben
US6808902B1 (en)	1999-11-12	2004-10-26	Amgen Inc.	Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
MXPA00011713A (es) *	2000-11-28	2002-05-31	Tgt Lab S A De C V	Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe
BRPI0209933B8 (pt) *	2001-05-24	2021-05-25	Zymogenetics Inc	proteína de fusão, e, molécula de ácido nucleico
EP1740615B1 (de)	2004-03-31	2014-11-05	Genentech, Inc.	Humanisierte anti-tgf-beta-antikörper
EP2862867A3 (de)	2005-10-25	2015-08-05	The Johns Hopkins University	Verfahren und Zusammensetzungen zur Behandlung des Marfan-Syndroms und assoziierter Erkrankungen
US8454952B2 (en)	2006-03-13	2013-06-04	The Johns Hopkins University	Augmentation of endothelial thromboresistance
US20100098668A1 (en) *	2006-09-29	2010-04-22	Northshore University Health System	Oncolytic Adenoviruses and Uses Thereof
MX2009003518A (es)	2006-10-03	2009-08-25	Genzyme Corp	Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.
WO2008157367A1 (en) *	2007-06-15	2008-12-24	Genzyme Corporation	Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
WO2009152610A1 (en)	2008-06-20	2009-12-23	The Royal Institution For The Advancement Of Learning/Mcgill University	Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
EP2547328B1 (de) *	2010-02-11	2017-06-07	Ecole Polytechnique Fédérale de Lausanne (EPFL)	Ccr7-liganden-verabreichung und co-verabreichung in einer immuntherapie
US9850296B2 (en)	2010-08-10	2017-12-26	Ecole Polytechnique Federale De Lausanne (Epfl)	Erythrocyte-binding therapeutics
WO2013121296A1 (en)	2012-02-15	2013-08-22	Ecole Polytechnique Federale De Lausanne	Erythrocyte-binding therapeutics
US9517257B2 (en)	2010-08-10	2016-12-13	Ecole Polytechnique Federale De Lausanne (Epfl)	Erythrocyte-binding therapeutics
EP2603520A4 (de)	2010-08-10	2014-02-19	Ecole Polytech	Erythrozytenbindende therapeutika
CN103429732B (zh)	2010-12-27	2015-09-16	Lsip基金运营联合公司	iPS细胞及其制造方法
CN102175501A (zh) *	2011-01-07	2011-09-07	山东省农业科学院作物研究所	用于显微镜观察的植物样品的前处理方法
US20140308275A1 (en)	2011-07-27	2014-10-16	Inserm (Institut National De La Sante Et De La Recherche Medicale	Methods for diagnosing and treating myhre syndrome
CN102898508B (zh) *	2011-08-12	2014-04-30	北京大学第一医院	封闭TGF-β受体或IL-10受体的多肽、其药物组合物及其用途
AU2011379972B2 (en)	2011-10-26	2016-05-12	Seattle Children's Research Institute	Cysteamine in the treatment of fibrotic disease
ES2897740T3 (es)	2011-12-28	2022-03-02	Kyoto Prefectural Public Univ Corp	Normalización del cultivo de células endoteliales de la córnea
HK1225740A1 (zh) *	2013-08-22	2017-09-15	Acceleron Pharma Inc.	TGF-β受体II型变体及其用途
CA2927898C (en)	2013-10-31	2021-11-16	Kyoto Prefectural Public University Corporation	Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
ES2902533T3 (es) *	2013-11-21	2022-03-28	Brigham & Womens Hospital Inc	Composiciones y métodos para tratar la hipertensión pulmonar
AR098827A1 (es)	2013-12-19	2016-06-15	Consejo Nac De Investig Científicas Y Técnicas (Conicet)	ISOFORMA DEL RECEPTOR II DE TGF-b, POLINUCLEÓTIDOS QUE LA CODIFICAN VECTORES, CÉLULAS TRANSFORMADAS, PÉPTIDOS Y DE FUSIÓN, MÉTODO Y USOS
BR112016014952A2 (pt) *	2014-02-10	2017-09-19	Merck Patent Gmbh	Inibição direcionada de tgfbeta
US10946079B2 (en)	2014-02-21	2021-03-16	Ecole Polytechnique Federale De Lausanne	Glycotargeting therapeutics
SG11201606761RA (en)	2014-02-21	2016-09-29	Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto	Glycotargeting therapeutics
US10046056B2 (en)	2014-02-21	2018-08-14	École Polytechnique Fédérale De Lausanne (Epfl)	Glycotargeting therapeutics
US10953101B2 (en)	2014-02-21	2021-03-23	École Polytechnique Fédérale De Lausanne (Epfl)	Glycotargeting therapeutics
EP3174550B1 (de)	2014-08-01	2020-01-29	The Brigham and Women's Hospital, Inc.	Verfahren und zusammensetzungen zur behandlung von pulmonal-arterieller hypertonie
WO2016187312A1 (en)	2015-05-18	2016-11-24	The Arizona Board Of Regents On Behalf Of The University Of Arizona	Methods and compositions for treating an alphavirus infection
CN108348578B (zh)	2015-08-04	2022-08-09	阿塞勒隆制药公司	用于治疗骨髓增生性病症的方法
US20200231652A1 (en)	2015-08-31	2020-07-23	National Research Council Of Canada	Tgf-b-receptor ectodomain fusion molecules and uses thereof
MX2018014256A (es) *	2016-05-20	2019-08-16	Harvard College	Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.
BR112019005964A2 (pt) *	2016-09-27	2019-06-18	Epicentrx, Inc.	proteínas de fusão imunomoduladoras
AU2018228435C1 (en) *	2017-03-02	2025-09-18	National Research Council Of Canada	TGF-beta-receptor ectodomain fusion molecules and uses thereof
ES2948647T3 (es)	2017-05-04	2023-09-15	Acceleron Pharma Inc	Proteínas de fusión del receptor TGF-beta tipo II y usos de las mismas
WO2018232176A1 (en)	2017-06-16	2018-12-20	The University Of Chicago	Compositions and methods for inducing immune tolerance
JP2020536518A (ja)	2017-09-27	2020-12-17	エピセントアールエックス，インコーポレイテッド	免疫調節融合タンパク質
MX2020009272A (es)	2018-03-06	2021-01-08	Univ Pennsylvania	Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
WO2019173692A2 (en)	2018-03-09	2019-09-12	Agenus Inc.	Anti-cd73 antibodies and methods of use thereof
US11168138B2 (en)	2018-03-26	2021-11-09	Altor Bioscience, Llc	Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
EP3790577A4 (de)	2018-05-09	2022-04-27	The University of Chicago	Zusammensetzungen und verfahren im zusammenhang mit immuntoleranz
AU2019301070B2 (en)	2018-07-09	2025-09-11	Precigen, Inc.	Fusion constructs and methods of using thereof
EP3947737A2 (de)	2019-04-02	2022-02-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren zur vorhersage und vorbeugung von krebs bei patienten mit prämalignen läsionen
US20220362333A1 (en) *	2019-07-26	2022-11-17	Board Of Trustees Of Michigan State University	Methods Of Preventing Or Treating Fatty Degeneration Of Skeletal Muscle
US20210061871A1 (en) *	2019-08-29	2021-03-04	Nantbio, Inc.	Modified N-810 and Methods Therefor
WO2021092079A1 (en) *	2019-11-05	2021-05-14	Acceleron Pharma Inc.	Treatments for systemic sclerosis
WO2022011256A1 (en)	2020-07-10	2022-01-13	Precigen, Inc.	Fusion constructs and methods of using thereof
CN113968903A (zh) *	2020-07-24	2022-01-25	迈威(上海)生物科技股份有限公司	TGF-β RII突变体及其融合蛋白
US11945856B2 (en)	2022-01-28	2024-04-02	35Pharma Inc.	Activin receptor type IIB variants and uses thereof
US20250152670A1 (en) *	2022-04-28	2025-05-15	Wenzhou Prarucom Bio-Chemical Technology Co.	Method for alleviating pulmonary fibrosis using epidermal growth factor
CN116676344A (zh) *	2023-05-31	2023-09-01	中国人民解放军总医院第八医学中心	稳定表达TGF-βII型受体的工程化巨噬细胞及其在肺纤维化治疗中的应用
US20260092096A1 (en)	2024-05-14	2026-04-02	35Pharma Inc.	Activin receptor type iib variants and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en) *	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4874702A (en) *	1980-09-08	1989-10-17	Biogen, Inc.	Vectors and methods for making such vectors and for expressive cloned genes
US4588585A (en) *	1982-10-19	1986-05-13	Cetus Corporation	Human recombinant cysteine depleted interferon-β muteins
US4797368A (en) *	1985-03-15	1989-01-10	The United States Of America As Represented By The Department Of Health And Human Services	Adeno-associated virus as eukaryotic expression vector
US4683195A (en) *	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5399346A (en) *	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
US6129914A (en) *	1992-03-27	2000-10-10	Protein Design Labs, Inc.	Bispecific antibody effective to treat B-cell lymphoma and cell line
DE69332026T2 (de) *	1992-10-29	2002-10-31	Celtrix Pharmaceuticals, Inc.	Typ ii tgf-beta-bindendes rezeptorfragment als therapeutisches mittel
ATE161730T1 (de) *	1993-02-09	1998-01-15	Biogen Inc	Antikörper zur behandlung von insulinabhängigen diabetes
US5925351A (en) *	1995-07-21	1999-07-20	Biogen, Inc.	Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease

1998
- 1998-04-16 NZ NZ500284A patent/NZ500284A/en unknown
- 1998-04-16 DK DK98918247T patent/DK0975771T3/da active
- 1998-04-16 CA CA002286933A patent/CA2286933A1/en not_active Abandoned
- 1998-04-16 AT AT98918247T patent/ATE366816T1/de not_active IP Right Cessation
- 1998-04-16 TR TR1999/02878T patent/TR199902878T2/xx unknown
- 1998-04-16 PT PT98918247T patent/PT975771E/pt unknown
- 1998-04-16 JP JP54615098A patent/JP2001515360A/ja not_active Withdrawn
- 1998-04-16 PL PL98336306A patent/PL336306A1/xx unknown
- 1998-04-16 KR KR1019997009624A patent/KR20010006534A/ko not_active Withdrawn
- 1998-04-16 AU AU71208/98A patent/AU737106B2/en not_active Ceased
- 1998-04-16 IL IL13224998A patent/IL132249A0/xx unknown
- 1998-04-16 EP EP98918247A patent/EP0975771B1/de not_active Expired - Lifetime
- 1998-04-16 ES ES98918247T patent/ES2289778T3/es not_active Expired - Lifetime
- 1998-04-16 BR BR9808934-0A patent/BR9808934A/pt not_active IP Right Cessation
- 1998-04-16 DE DE69838061T patent/DE69838061T2/de not_active Expired - Fee Related
- 1998-04-16 EA EA199900947A patent/EA199900947A1/ru unknown
- 1998-04-16 CN CN98805473A patent/CN1257545A/zh active Pending
- 1998-04-16 WO PCT/US1998/007587 patent/WO1998048024A1/en not_active Ceased
- 1998-04-16 EE EEP199900492A patent/EE9900492A/xx unknown
1999
- 1999-10-14 NO NO994998A patent/NO994998L/no not_active Application Discontinuation
- 1999-10-15 IS IS5217A patent/IS5217A/is unknown
2005
- 2005-04-18 US US11/108,597 patent/US20050203022A1/en not_active Abandoned
2008
- 2008-01-11 JP JP2008005068A patent/JP2008106076A/ja active Pending

Also Published As

Publication number	Publication date
IS5217A (is)	1999-10-15
WO1998048024A1 (en)	1998-10-29
EE9900492A (et)	2000-06-15
KR20010006534A (ko)	2001-01-26
DE69838061T2 (de)	2008-03-13
AU737106B2 (en)	2001-08-09
ES2289778T3 (es)	2008-02-01
EP0975771A1 (de)	2000-02-02
PT975771E (pt)	2007-10-01
US20050203022A1 (en)	2005-09-15
EA199900947A1 (ru)	2000-04-24
BR9808934A (pt)	2000-08-01
NO994998D0 (no)	1999-10-14
JP2008106076A (ja)	2008-05-08
PL336306A1 (en)	2000-06-19
IL132249A0 (en)	2001-03-19
NZ500284A (en)	2001-09-28
DK0975771T3 (da)	2007-10-22
JP2001515360A (ja)	2001-09-18
EP0975771B1 (de)	2007-07-11
AU7120898A (en)	1998-11-13
ATE366816T1 (de)	2007-08-15
TR199902878T2 (xx)	2000-02-21
CN1257545A (zh)	2000-06-21
CA2286933A1 (en)	1998-10-29
DE69838061D1 (de)	2007-08-23

Legal Events

Date	Code	Title	Description
2003-12-08	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO994998L (no)	1999-12-20	Fusjonsproteiner
KR950700779A (ko)	1995-02-20	단백질의 정제방법(Protein purification)
CY2005008I1 (el)	2009-11-04	Αντισωματα αντι - vegf
DE69536078D1 (de)	2010-07-01	Inhibitoren
DK0911416T3 (da)	2006-08-14	Fremgangsmåde til fremstilling af protein
PT1087013E (pt)	2009-04-15	Imunoglobtainas desprovidas de cadeias leves
BR9507100A (pt)	1997-09-16	Purificação de anticorpos
DK1200479T3 (da)	2006-05-15	Multiple cytokin-antistof-komplekser
DE69833014D1 (de)	2006-02-02	Menschliche toll homologen
FI964845A7 (fi)	1996-12-04	CD44v6:n vastaiset monoklonaaliset vasta-aineet
DK0917879T3 (da)	2002-11-04	Forbedret fremgangsmåde til stabilisering af proteiner
PT1027339E (pt)	2004-05-31	Metodo e reagentes para a n-alquilacao de ureidos
DE69828154D1 (de)	2005-01-20	Anti-alphavbeta3 humanizierte monoklonale antikörper
BR9708347A (pt)	1999-08-03	Compostos de tetrahidorbeta-carbonila
DE69634077D1 (de)	2005-01-27	Haemophilus adhäsionsproteinen
DK0829579T3 (da)	2003-07-21	Farbart bindelag og fremgangsmåde til den fremstilling
CY1106887T1 (el)	2012-09-26	Πρωτεϊνες συντηξης τυπου ii tgf-b υποδοχεα/σταθερης περιοχης ανοσοσφαιρινης
BR9805546B1 (pt)	2011-03-09	regulador de alternador polifásico de veìculo automotor.
ES1036274Y (es)	1998-01-16	Conjunto de piezas de suspension de lamparas.
BR1100492A (pt)	2008-05-06	variantes de imunoglobulina.
BR1100555B1 (pt)	2009-01-13	anticorpos monoclonais humanizados.
SK973U (sk)	1995-10-11	Spojovací článok pre izolátor
ES1037390Y (es)	1998-07-01	Pieza para empalme de vigas.
KR970032618U (ko)	1997-07-26	자동차의 전조등 조정장치
NL1002496A1 (nl)	1996-07-11	Loopwagen.